Analysts expect EPS of $3.04, 74.7% above the year-earlier quarter; revenue consensus stands at $644.84 million, up 39.2%.
The consensus puts EPS at $3.04 per share and revenue at $644.84 million.
Business
The consensus puts earnings per share at $3.04 and revenue at $644.84 million, with revenue growth projected at 39.2%.

Analysts expect EPS of $3.04, 74.7% above the year-earlier quarter; revenue consensus stands at $644.84 million, up 39.2%.
The consensus puts EPS at $3.04 per share and revenue at $644.84 million.
The count measures how often forecasts were topped, not the size of the earnings surprises.
Adjusted diluted EPS was $3.82, while immunology revenue rose 16.3% to $9.165 billion.
Revenue increased 6% to $1.415 billion, and the company maintained its fiscal 2027 sales and earnings outlook.